ESMO Reaction
September 15, 2022

ESMO Reactions: TROPiCS-2

ESMO Reaction
September 15, 2022

ESMO Reactions: TROPiCS-2

Author

Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) inpatients with HR+/HER2- metastatic breast cancer.

Abstract #LBA76: Hope Rugo presented interim OS results from the P3 TROPiCS-02 trial, which compared sacituzumabgovitecan (SG) (n=272) vs physician’s choice (n=271) in heavily pre-treated HR+/HER2- endocrine-resistant, unresectable locally advanced or metastatic breast cancer.

Results: SGdemonstrated significant improvement in OS (median: 14.4 vs 11.2 months for TPC),and significant improvement in objective response rate (21% vs 14%) and quality of life.

Thought leader reactions were moderately positive, with several welcoming any OS benefit in a population with limited treatment options. Comparisons to recent PFS data were positive:

However, some questioned the importance ofan overall survival benefit of only three months:

Several commentators hope and expect FDA approval for sacituzumab govitecan in this population:

One KOL would like to know the impact of this data on Trop-2 negative breast cancer patients and wonders why Trop-2 expression was not assessed.

Summary:

This interim analysis of TROPiCS-2 OS data represents a positive step for this small population with limited treatment options. Some, however, consider the data only “incremental” or “modest”instead of game changing. Still, thought leaders expect FDA approval for sacituzumabgovite can in this population.

Synthesis by Opus Strategy, LLC

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.